Nurix Therapeutics outlines 2024 priorities: BTK degrader NX-5948 acceleration, partial hold on NX-2127

Nurix Therapeutics, Inc.

Positive Phase 1 data for NX-5948 (BTK degrader) in CLL/NHL; plans to accelerate enrollment toward pivotal trials.
NX-2127 Phase 1 partial clinical hold; Nurix expects to resolve with new drug product in ongoing trial.
Gilead licensed oral IRAK4 degrader NX-0479 for $20M fee; up to $425M milestones plus tiered royalties.
Pfizer (Seagen) collaboration for Degrader-Antibody Conjugates; $60M upfront, up to $3.4B milestones.
Cash of $329M (Aug 2023) plus $60M from Pfizer; runway into H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.